- Home
- CING vs BCLI Comparison
CING vs BCLI Comparison
Compare CING & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CING
- BCLI
- Stock Information
- Founded
- CING 2012
- BCLI 2000
- Country
- CING United States
- BCLI United States
- Employees
- CING N/A
- BCLI N/A
- Industry
- CING Biotechnology: Pharmaceutical Preparations
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CING Health Care
- BCLI Health Care
- Exchange
- CING Nasdaq
- BCLI Nasdaq
- Market Cap
- CING 15.3M
- BCLI 13.5M
- IPO Year
- CING 2021
- BCLI N/A
- Fundamental
- Price
- CING $4.76
- BCLI $1.89
- Analyst Decision
- CING Strong Buy
- BCLI Strong Buy
- Analyst Count
- CING 2
- BCLI 1
- Target Price
- CING $12.00
- BCLI $30.00
- AVG Volume (30 Days)
- CING 216.3K
- BCLI 109.6K
- Earning Date
- CING 11-07-2024
- BCLI 11-14-2024
- Dividend Yield
- CING N/A
- BCLI N/A
- EPS Growth
- CING N/A
- BCLI N/A
- EPS
- CING N/A
- BCLI N/A
- Revenue
- CING N/A
- BCLI N/A
- Revenue This Year
- CING N/A
- BCLI N/A
- Revenue Next Year
- CING N/A
- BCLI N/A
- P/E Ratio
- CING N/A
- BCLI N/A
- Revenue Growth
- CING N/A
- BCLI N/A
- 52 Week Low
- CING $1.80
- BCLI $1.05
- 52 Week High
- CING $62.70
- BCLI $11.85
- Technical
- Relative Strength Index (RSI)
- CING 52.86
- BCLI 44.80
- Support Level
- CING $4.27
- BCLI $1.90
- Resistance Level
- CING $5.16
- BCLI $2.17
- Average True Range (ATR)
- CING 0.42
- BCLI 0.18
- MACD
- CING -0.01
- BCLI -0.05
- Stochastic Oscillator
- CING 37.18
- BCLI 4.76
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.